OR4A15: A Potential Drug Target and Biomarker for Ovarian Cancer
OR4A15: A Potential Drug Target and Biomarker for Ovarian Cancer
Ovarian cancer is the leading cause of cancer death in women, with over 21,000 new cases and 15,000 deaths in the United States alone in 2019. Despite advances in treatment, the survival rate for ovarian cancer has remained relatively stagnant in recent years. Therefore, there is a need for new and effective treatments to improve outcomes for patients.
One potential drug target for ovarian cancer is the OR4A15 receptor, also known as olfactory receptor OR11-118. OR4A15 is a G protein-coupled receptor (GPCR) that is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract. OR4A15 has been shown to play a role in the development and progression of ovarian cancer.
Studies have shown that high expression of OR4A15 is associated with poor prognosis in ovarian cancer patients. In addition, downregulation of OR4A15 has been shown to enhance the sensitivity of ovarian cancer cells to chemotherapy. Therefore, targeting OR4A15 may be a promising strategy for the development of new treatments for ovarian cancer.
One potential way to target OR4A15 is through the use of small molecules (SMMs). SMMs are drugs that can interact with a protein to alter its activity. There is a growing body of research on the use of SMMs as potential therapeutic agents for a variety of diseases, including ovarian cancer.
One of the most promising SMMs for targeting OR4A15 is a compound called NK-4219. NK-4219 is a small molecule that binds to the OR4A15 receptor and has been shown to reduce the growth of ovarian cancer cells in cell culture and animal models. In addition, NK-4219 has been shown to induce apoptosis (programmed cell death) in ovarian cancer cells, which may be an effective way to target the disease.
Another potential SMM for targeting OR4A15 is a compound called VEGF-16. VEGF-16 is a growth factor that has been shown to stimulate the growth and survival of various cell types, including ovarian cancer cells. In addition, VEGF-16 has been shown to promote the angiogenesis (the formation of new blood vessels) in ovarian cancer, which may contribute to the development of the disease.
While NK-4219 and VEGF-16 have shown promise as potential SMMs for targeting OR4A15, further studies are needed to determine their safety and effectiveness in the treatment of ovarian cancer. In addition, there is a need for additional compounds that can be used to optimize the efficacy of SMMs for targeting OR4A15.
Targeting OR4A15 may also be a potential biomarker for ovarian cancer. By measuring the expression and function of OR4A15 in ovarian cancer cells, researchers may be able to monitor the effectiveness of different treatments and identify potential biomarkers for the disease. This information could be valuable for the development of new and more effective treatments for ovarian cancer.
In conclusion, OR4A15 is a promising drug target and biomarker for ovarian cancer. The use of small molecules such as NK-4219 and VEGF-16 has shown promise in targeting the OR4A15 receptor and promoting the growth and survival of ovarian cancer cells. Further studies are needed to determine the safety and effectiveness of these SMMs
Protein Name: Olfactory Receptor Family 4 Subfamily A Member 15
Functions: Odorant receptor
The "OR4A15 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR4A15 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P | OR4V1P | OR4X1 | OR4X2 | OR51A1P | OR51A2 | OR51A3P | OR51A4 | OR51A6P | OR51A7 | OR51B2 | OR51B4 | OR51B5 | OR51B6 | OR51C1P | OR51D1 | OR51E1 | OR51E2 | OR51F1 | OR51F2 | OR51G1 | OR51G2 | OR51H1 | OR51I1 | OR51I2 | OR51J1 | OR51L1 | OR51M1 | OR51Q1 | OR51S1 | OR51T1 | OR51V1 | OR52A1 | OR52A4P | OR52A5 | OR52B2 | OR52B4 | OR52B6 | OR52D1 | OR52E1 | OR52E2 | OR52E4
